Bio & Medicine
L&C Bio to list shares on KOSDAQ
- PUBLISHED :August 31, 2018 - 15:22
- UPDATED :August 31, 2018 - 15:22
[THE INVESTOR] L&C Bio, a tissue engineering company, said on Aug. 31 it has gained preliminary approval for its initial public offering on Korea‘s secondary bourse KOSDAQ.
The company plans to float 13.8 percent of its shares, or 1 million stocks, through the IPO. The price band for the offer will be between 18,000 won (US$16.17) and 20,000 won. Korea Investment & Securities is the main underwriter for the IPO.
L&C Bio has been reaping sales growth, from 2.7 billion won in 2012 to 17.9 billion won last year, by developing acellular dermal matrix and allogenic bone with various tissue regeneration and tissue reconstruction techniques. It offers solutions in orthopedic, spine, burn and wound procedures to help restore a patient’s health and mobility.
In 2017, the company reported 4.9 billion won in operating income and 3.8 billion won net profit.
Its product lineup also includes cosmeceutical items, including a cream-type treatment for atopic skin disease.
By Park Han-na (firstname.lastname@example.org)